# David M. Rubin

> David M. Rubin is a Series B investor at Merck Global Health Innovation Fund backing Biotechnology. See 20 investments, check sizes, portfolio. Updated Aug…

- Type: Angel Investor
- Fund: [Merck Global Health Innovation Fund](https://shizune.co/investors/profile/merck-global-health-innovation-fund)
- Location: Philadelphia, United States
- Total investments: 20
- Last investment: Feb 2026
- Lead investor: 75%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/david-rubin-5b64b4

David M. Rubin is a Series B investor at Merck Global Health Innovation Fund in Philadelphia focused on Biotechnology and Health Care. David M. Rubin - Managing Director, Merck Global Health Innovation Fund; AVP, Merck & Co @ Merck

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 10 | 50% |
| Health Care | 9 | 45% |
| Pharmaceutical | 3 | 15% |
| Clinical Trials | 3 | 15% |
| Health Diagnostics | 3 | 15% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 6 | 30% |
| Series A | 4 | 20% |
| Funding Round | 2 | 10% |
| Private Equity | 2 | 10% |
| Series C | 1 | 5% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 10 | 50% |
| Hungary | 1 | 5% |
| United Kingdom | 1 | 5% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Turbine | Turbine builds a platform to understand the inner mechanisms of cancer, enabling the discovery of novel protein targets, precision biomarkers, and better translation to patients. Turbine uses its proprietary Simulated Cell technology in combination with Artificial Intelligence to build a faster and deeper biological understanding of therapeutictargets or indications, untangling the complexity of cancer. | $25M | Series B | Feb 24, 2026 |  |
| Octave | Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States. | $35.6M | Series C | Sep 04, 2025 |  |
| N-Power Medicine | N-Power Medicine specializes in drug development and clinical research. | $72M | Series B | May 21, 2024 |  |
| Baseimmune | Baseimmune is a biotech startup founded to create the next generation of vaccines. | $11.4M | Series A | Feb 26, 2024 |  |
| Culmination Bio | Culmination Bio is a startup that is developing a disease-independent patient data intelligence platform. | $10M | Series A | Nov 30, 2023 |  |
| Octave | Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States. | $30M | Series B | Jul 26, 2023 |  |
| Turbine | Turbine builds a platform to understand the inner mechanisms of cancer, enabling the discovery of novel protein targets, precision biomarkers, and better translation to patients. Turbine uses its proprietary Simulated Cell technology in combination with Artificial Intelligence to build a faster and deeper biological understanding of therapeutictargets or indications, untangling the complexity of cancer. | $20.6M | Series A | Nov 22, 2022 |  |
| PreciseDx | PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient.Combining the power of artificial intelligence with its proprietary Morphology Feature Array™, PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making. | $10.8M | Series A | Jan 11, 2022 |  |
| Verge Genomics | Verge Genomics transforms drug discovery with artificial intelligence. Verge was founded by a unique combination of the field's top machine learning experts and seasoned neuroscience drug developers. Together, they share the vision that exponential advances in computational genomics combined with new insights into neuroscience has created abreakthrough opportunity to discover drugs that dramatically improve the lives of patients suffering from neurodegenerative disease. | $98M | Series B | Dec 16, 2021 |  |
| Saama | Saama is the number one AI-powered clinical analytics cloud platform company, unleashing wisdom from data to deliver better business outcomes for the life sciences industry. Saama’s unified, AI-driven clinical data analytics platform seamlessly integrates, curates, and animates unlimited sources of structured, unstructured, and real-world data todeliver actionable insights across all therapeutic areas. The award-winning platform gives unprecedented real-time visibility into clinical data, enabling sponsors to file New Drug Applications (NDAs) more efficiently to bring drugs to market faster and at lower costs. For more information, visit http://www.saama.com. |  | Private Equity | Oct 20, 2021 |  |

10 of 20 investments shown.

## Co-investors
- [Aberdare Ventures](https://shizune.co/investors/profile/aberdare-ventures) — VC Fund, 3 deals together
- [Bay City Capital](https://shizune.co/investors/profile/bay-city-capital) — VC Fund, 3 deals together
- [Intermountain Ventures](https://shizune.co/investors/profile/intermountain-ventures) — VC Fund, 3 deals together
- [New Leaf Venture Partners](https://shizune.co/investors/profile/new-leaf-venture-partners) — VC Fund, 3 deals together
- [Northpond Ventures](https://shizune.co/investors/profile/northpond-ventures) — VC Fund, 3 deals together
- [S32](https://shizune.co/investors/profile/section-32) — VC Fund, 3 deals together

## About Merck Global Health Innovation Fund

VC Fund · Whitehouse Station, United States

Merck Global Health Innovation Fund (Merck GHI) is evolving corporate healthcare venture capital globally by utilizing their healthcare ecosystem strategy. This investment strategy connects innovative companies with complementary technologies to develop integrated healthcare solutions.Merck GHI has $500M under management and provides growthcapital to emerging healthcare technology companies worldwide while leveraging the vast R&D-based, global resources of Merck.With a vision that data will be the currency in healthcare, GHI invests broadly in digital health. GHI invests in platform companies with proven technologies or business models where Merck's expertise and perspectives can accelerate revenue growth and enhance value creation. Since late 2010, Merck GHI has made over 20 investments in Digital Health companies.

5 contacts available at Merck Global Health Innovation Fund.

| Name | Title | Profile |
| --- | --- | --- |
| Bill Taranto | Founder, President & General Partner | https://shizune.co/investors/profile/william-taranto |
| Bill Taranto | Founder, President & General Partner | https://shizune.co/investors/profile/bill-taranto |
| Dave Stevenson | Managing Director | https://shizune.co/investors/profile/dave-stevenson |
| Joe Volpe | Managing Director and Founding Partner | https://shizune.co/investors/profile/joe-volpe |
| David M. Rubin | Managing Director | https://shizune.co/investors/profile/david-m-rubin |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does David M. Rubin invest in?

David M. Rubin invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did David M. Rubin last invest?

The most recent investment recorded for David M. Rubin closed in Feb 2026. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co